Press

Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences

Jan 18 • 4 min read

Highlights: Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that it has completed dosing and treatment protocols for all 72 participants in the PsiGAD-1 clinical trial, the Company’s Phase 2 study evaluating its own psilocybin treatment program for patients…

Clearmind Medicine Inc. Selects Aegis Capital Corp. as Sole Bookrunner for $2.4M Private Placement

Jan 18 • 2 min read

Aegis Capital Corp. acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ:CMND). About Clearmind Medicine Inc. Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and…

Filament Health Completes the First Export of Botanical Psilocybin to Australia

Jan 17 • 2 min read

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical‐stage natural psychedelic drug development company, today announced that it successfully completed an export of PEX010, the Company’s botanical psilocybin drug candidate, to Perth, Western Australia. The shipment is believed to be the first botanical psilocybin to be exported to Australia and was received…

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Jan 17 • 5 min read

Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that an independent Institutional Review Board (IRB) has approved the protocol for the Company’s Phase 2/3 clinical trial to be conducted in the United States to assess safety and efficacy of…

MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement

Jan 17 • 3 min read

The Multidisciplinary Association for Psychedelic Studies (MAPS) reintroduces its Fiscal Sponsorship Program, signaling a new era of support for grassroots organizations within the psychedelic ecosystem. With over 10 years of impactful collaboration, MAPS has fostered nearly 70 mission-aligned groups globally, advancing the movement for psychedelic harm reduction, drug policy reform, and education. Fiscal sponsorship is a…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435